(MENAFN- ProactiveInvestors)Shaun Chilton deputy CEO of pharma and services specialist Clinigen (LON:CLIN) says the company is eyeing up more acquisitions after a busy twelve months. Organic growth and acquisitions equally contributed to a 20% EBITDA growth in the year to 30 June. In August 2014 Clinigen strengthened its oncology support portfolio with the acquisition of Ethyol from AstraZeneca. More recently it added Idis for £225mln establishing the enlarged group as the market leader in the ethical supply of unlicensed medicines. In light of the Idis acquisition Clinigen has reviewed and restructured its management team with Chilton taking on the role of deputy CEO.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.